VEGFA and glioblastoma: Bevacizumab (BEV), a recombinant humanized monoclonal antibody against all isoforms of VEGFs, is the most frequently investigated VEGF inhibitor, with more than 100 clinical trials evaluating its efficacy singly or in combination for both primary and recurrent GBM patients.